Business Context and Reporting Period
This Form 8-K was filed by Pono Capital Two, Inc., a special purpose acquisition company, in connection with its proposed business combination with SBC Medical Group Holdings Inc. The report date is May 4, 2023, with subsequent events occurring on May 5 and May 8, 2023. The filing does not provide operating results for SBC Medical Group.
Key Financial and Capitalization Metrics
- Following stockholder redemptions, approximately $20.0 million remained in Pono’s trust account.
- Stockholders elected to redeem 9,577,250 shares of Class A common stock.
- Following the redemptions and sponsor conversion, Pono had 5,489,624 Class A shares outstanding, including 3,566,874 shares held by initial stockholders and not subject to redemption, and one Class B share outstanding.
- The Sponsor converted 2,874,999 Class B shares into an equal number of Class A shares on May 8, 2023.
- No revenue, profit, cash-flow, margin, debt, or liquidity metrics for SBC Medical Group are provided in this filing.
Material Changes and Transactions
- On May 3, 2023, Pono entered into non-redemption agreements covering 773,682 public shares. On May 4, it entered into an additional agreement covering 225,000 shares, for an aggregate of 998,682 shares subject to such agreements.
- In exchange for the non-redemption commitments, the Sponsor agreed to transfer shares of Pono common stock to the participating stockholders upon consummation of the initial business combination.
- Stockholders approved an amendment extending Pono’s deadline to complete a business combination from May 9, 2023 to February 9, 2024.
- The amendment also permitted holders of Class B common stock to convert their shares into Class A common stock on a one-for-one basis before the business combination.
- The charter amendment became effective upon filing with the Delaware Secretary of State on May 8, 2023.
Outlook, Risks, and Unusual Items
The filing provides no formal financial guidance or operating outlook. Pono stated that it intends to pursue the proposed business combination and related proxy process. Completion remains subject to applicable conditions, including stockholder approval and other closing requirements.
- Key risks include failure to complete the business combination, termination of the merger agreement, litigation, higher-than-expected redemptions, and failure to satisfy Nasdaq listing standards.
- Pono and SBC may need additional capital, which may not be available on acceptable terms or at all.
- The proposed transaction could disrupt SBC’s business relationships, operations, and strategic plans.
- The filing identifies uncertainty regarding SBC’s future revenue, capital expenditures, liquidity, financial performance, market opportunity, and the expected benefits of the transaction.
- The substantial redemptions reduced the funds remaining in trust and may affect the capital available after the transaction.
Important Facts to Verify
- Whether the proposed business combination with SBC Medical Group is ultimately completed by the extended deadline of February 9, 2024.
- The final number of shares redeemed, the resulting ownership structure, and the amount ultimately available from the trust account.
- The terms and aggregate value of the Sponsor’s share transfers under the non-redemption agreements.
- The financial condition, revenue, profitability, cash flow, debt, and liquidity of SBC Medical Group, which are not disclosed in this filing.
- The definitive proxy statement, merger agreement, transaction valuation, financing arrangements, and any additional redemption or capital requirements.